NCT05222412 is a clinical trial of Iptacopan in C3 Glomerulopathy (C3G), sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05222412?

NCT05222412 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05222412?

Interventions in NCT05222412: Iptacopan.

What condition does NCT05222412 study?

NCT05222412 studies C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH).

Is NCT05222412 still recruiting?

NCT05222412 is currently available. Last updated 5 December 2025.

Last reviewed 2025-12-05 · How we verify

NCT05222412

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Managed Access Programs for LNP023, Iptacopan

AVAILABLE Last updated 5 December 2025

What this trial tests

trial testing Iptacopan in C3 Glomerulopathy (C3G). Available.

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	AVAILABLE
Study type	EXPANDED_ACCESS

Drugs / interventions tested

Iptacopan (IPTACOPAN) — full drug profile →

Conditions studied

C3 Glomerulopathy (C3G) — all drugs for C3 Glomerulopathy (C3G) →
Paroxysmal Nocturnal Hemoglobinuria (PNH) — all drugs for Paroxysmal Nocturnal Hemoglobinuria (PNH) →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with C3 Glomerulopathy (C3G) or Paroxysmal Nocturnal Hemoglobinuria (PNH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.
Schmidt CQ, Smith RJH. · · 2023 · cited 21× · PMID 36398537 · DOI 10.1111/imr.13164
Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study.
Münch J, Sessler I, Bosse HM, Wargenau M, et al · · 2023 · cited 6× · PMID 37376177 · DOI 10.3390/pharmaceutics15061729
Monogenic Kidney Diseases in Kidney Transplantation.
Gillion V, Devresse A, Olinger E, Dahlqvist G, et al · · 2024 · cited 3× · PMID 38481491 · DOI 10.1016/j.ekir.2023.12.003

Verify or expand the search:

Other trials of Iptacopan

Trials testing the same drug.

NCT07331259 — CHART-C3G/CLNP023B12011 · not yet recruiting
NCT06903234 — Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data · active not recruiting
NCT06952426 — A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the · recruiting
NCT06847607 — A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA) · NA · not yet recruiting
NCT06797518 — Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN · Phase 2 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05222412 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 5 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05222412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing